Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 jan 2016 - 08:10
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Key patents granted for Probiodrug's pGlu-Abeta targeting monoclonal antibody program for the treatment of Alzheimer's disease
Bericht
Key patents granted for Probiodrug's pGlu-Abeta targeting monoclonal antibody program for the treatment of Alzheimer's disease
HALLE/SAALE, Germany, 11 January 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announces, that key patents for its antibody program targeting pyroglutamate Abeta (pGlu-Abeta, also N3pG Abeta), were granted during the last quarter of 2015. Patents US 9,156,907 and JP 5,828,762, were granted in the US and in Japan, respectively, covering method as well as composition of matter claims.
Gerelateerde downloads
Datum laatste update: 01 september 2024